Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1

Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1

The monarchE Cohort 1 patient population was enrolled based on high-risk clinicopathological features that can easily be identified as part of routine clinical breast cancer evaluation. Efficacy data from Cohort 1 demonstrate substantial evidence of benefit for adjuvant abemaciclib+ET in patients wi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The oncologist (Dayton, Ohio) Ohio), 2023-01, Vol.28 (1), p.e77-e81
Hauptverfasser: Toi, Masakazu, Boyle, Frances, Im, Young-Hyuck, Reinisch, Mattea, Molthrop, David, Jiang, Zefei, Wei, Ran, Sapunar, Francisco, Grimes, Brenda R, Nabinger, Sarah Cassidy, Johnston, Stephen R D
Format: Artikel
Sprache:eng
Schlagworte:
Aminopyridines - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Benzimidazoles - therapeutic use
Breast cancer
Breast Neoplasms - pathology
Care and treatment
Complications and side effects
Diagnosis
Female
Health aspects
Hormone therapy
Humans
Medical colleges
Patient outcomes
Pharmaceutical industry
Protein Kinase Inhibitors - therapeutic use
Receptor, ErbB-2 - therapeutic use
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The monarchE Cohort 1 patient population was enrolled based on high-risk clinicopathological features that can easily be identified as part of routine clinical breast cancer evaluation. Efficacy data from Cohort 1 demonstrate substantial evidence of benefit for adjuvant abemaciclib+ET in patients with HR+, HER2- early breast cancer at high risk of recurrence (ClinicalTrials.gov: NCT03155997 [monarchE]).
ISSN:1083-7159
1549-490X
DOI:10.1093/oncolo/oyac234